Ranibizumab biosimilar (Senju)

雷珠单抗生物类似药 (Senju)

Report date: 2023/12/14 14:27:45

Base Information

Drug NameRanibizumab biosimilar (Senju)
Drug Alias NameRanibizumab biosimilar - Gene Techno Science雷珠单抗生物仿制药 (Senju)Ranibizumab BSGBS-007OT-701 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragment
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsMacular Degeneration
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2021/09/27
Country/TerritoryMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPreclinical
Originator CompaniesSenju Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOcumension Therapeutics (Shanghai) Co LtdSenju Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeS01LA04
Related LinksN/A